Overview

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Status:
Completed
Trial end date:
2009-06-26
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the safety and efficacy of PF-04217329.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Latanoprost
Criteria
Inclusion Criteria:

- Diagnosis of primary open-angle glaucoma (including pigmentary or pseudoexfoliative)
or ocular hypertension in 1 or both eyes.

- Qualifying intraocular pressure (IOP) in the same eye at the Eligibility 1 and 2
measurements.

Exclusion Criteria:

- Closed/barely open anterior chamber angle or a history of acute angle closure in
either eye.

- Anticipate the need to initiate or modify medication (systemic or topical) that is
known to affect intraocular pressure (IOP) during the study period.